NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial
SAN DIEGO/November 10, 2015 --(BUSINESS WIRE)--NeuroGenetic Pharmaceuticals, Inc. (NGP), a privately held biopharmaceutical company focused on Alzheimer’s disease (AD...


